Krystal Biotech (KRYS) fundamentals: P/E, valuation, undervalued?
Krystal Biotech · Health Care · ref. ETF XLV · price $321.16
In short — Krystal Biotech trades at 40.2× earnings (P/E), 34.7× forward, with a net margin of 54.8 % and revenue growth of +24 %. Read: Cheap for the growth (P/E 35 for ~39% growth (PEG 0.9)).
Is Krystal Biotech stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$321.16+70.8% over range
Oct 14, 25low $185.05 · high $378.15Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 6 analysts
Valuation : Cheap for the growth — P/E 35 for ~39% growth (PEG 0.9)
Valuation
40.2
P/E (price/earnings)
34.7
Forward P/E
1.04
PEG
7.0
Price/book (P/B)
$9.5B
Market cap
7.98
EPS
Profitability & growth
54.8 %
Net margin
+24 %
Revenue growth
+39 %
Earnings growth
$9M
Total debt
Krystal Biotech income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $0 | $-140M | — |
| 2023 | $51M | $11M | 21.6 % |
| 2024 | $291M | $89M | 30.7 % |
| 2025 | $389M | $205M | 52.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Krystal Biotech's P/E and is the stock undervalued? What's a good P/E?
Krystal Biotech's P/E is 40.2 (forward 34.7). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Krystal Biotech profitable?
Krystal Biotech has a net margin of 54.8 % (EPS 7.98). The company is profitable.
Is KRYS stock expensive?
Our read: "Cheap for the growth" — P/E 35 for ~39% growth (PEG 0.9). Cross-check with growth and sector.
💬 A question about Krystal Biotech? The JPI assistant answers using our backtest data.
Keep exploring Krystal Biotech